<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030771</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 16/00</org_study_id>
    <secondary_id>SWS-SAKK-16/00</secondary_id>
    <secondary_id>EU-20138</secondary_id>
    <nct_id>NCT00030771</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients</brief_title>
  <official_title>Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells. Giving chemotherapy with radiation therapy before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed. It is not yet known if chemotherapy plus radiation therapy is more effective than&#xD;
      chemotherapy alone before surgery in treating non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying docetaxel and cisplatin with or without&#xD;
      radiation therapy to see how well they work when given before surgery in treating patients&#xD;
      with stage IIIA non-small cell lung cancer that has spread to lymph nodes in the chest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this trial is to compare feasibility and efficacy of sequential&#xD;
      neoadjuvant chemoradiotherapy with 44 Gy concomitant boost to neoadjuvant chemotherapy alone.&#xD;
&#xD;
      Secondary objectives are to assess the value of PET in predicting pathological response and&#xD;
      eventfree survival in stage IIIA NSCLC, and a health economic analysis of the two regimens.&#xD;
      Further to compare the amount of serum DNA in patients with stage IIIA, pN2 NSCLC before&#xD;
      chemotherapy, before surgery and at the second follow-up visit (i.e. four months after&#xD;
      surgery or treatment failure for patients who can not be operated) in patients randomized&#xD;
      into the trial SAKK 16/00 and to correlate the DNA variation with tumor response, remission&#xD;
      duration and overall survival.&#xD;
&#xD;
      OUTLINE: This is a prospective randomized phase III trial. Patients are stratified according&#xD;
      to mediastinal bulk (5 cm or more vs less than 5 cm), weight loss in the past 6 months (5% or&#xD;
      more vs less than 5%), and participating center. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2001</start_date>
  <completion_date type="Anticipated">December 2037</completion_date>
  <primary_completion_date type="Actual">April 9, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Time from randomization to relapse/progression/second tumor/death, whichever occurs first (for all randomized patients). If no event is observed, the patients will be censored at the last time they were known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality assessed</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>All deaths occurring within 30 days of the thoracic surgery to remove the primary tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities)</measure>
    <time_frame>During treatment</time_frame>
    <description>Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading. Special attention shall be given to hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resection rate after surgery</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate measured after completion of chemoradiotherapy</measure>
    <time_frame>43 days</time_frame>
    <description>Response rate will be evaluated according to the&#xD;
WHO response criteria&#xD;
TNM classification after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operability</measure>
    <time_frame>1 month after chemo</time_frame>
    <description>Patients who are able to undergo radical resection of their lung cancer after neoadjuvant therapy, as assessed by the thoracic surgeon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Life-long follow-up until death of patient (up to 30 years)</time_frame>
    <description>Calculated from randomization to the date of death from any cause. Patients not experiencing an event will be censored at the last time they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure pattern</measure>
    <time_frame>Life-long follow-up until death of patient (up to 30 years)</time_frame>
    <description>Defined as location of first tumor progression or relapse. Failure can be local relapse (area of primary tumor or mediastinum), distant relapse (all others) or the combination thereof.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant Chemotherapy + Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>3-4 weeks after termination of radiotherapy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Squamous, adenosquamous, large cell, or poorly differentiated&#xD;
&#xD;
          -  Stage IIIA (T1-3, N2, M0)&#xD;
&#xD;
               -  N2 disease confirmed by 1 of the following:&#xD;
&#xD;
                    -  Mediastinoscopy&#xD;
&#xD;
                    -  Bronchoscopy with fine-needle aspiration or esophagoscopy&#xD;
&#xD;
                         -  All N3 lymph nodes must be negative by positron-emission tomography&#xD;
                            (PET) AND CT scan (&lt; 1 cm in the largest diameter)&#xD;
&#xD;
                    -  PET scan&#xD;
&#xD;
                         -  Both the primary tumor and at least 1 N2 lymph node must be positive in&#xD;
                            PET scan&#xD;
&#xD;
                         -  At least 1 of the PET scan positive N2 lymph nodes is positive in the&#xD;
                            CT scan (&gt; 1 cm in the largest diameter)&#xD;
&#xD;
                         -  All N3 lymph nodes negative in PET scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac function normal&#xD;
&#xD;
          -  No unstable cardiac disease requiring treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris even if medically controlled&#xD;
&#xD;
          -  No significant arrhythmia&#xD;
&#xD;
          -  No myocardial infarction in the past 3 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Lung function appropriate&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorders&#xD;
&#xD;
          -  No psychotic disorders&#xD;
&#xD;
          -  No dementia&#xD;
&#xD;
          -  No seizures&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancies except nonmelanoma skin cancer, adequately&#xD;
             treated carcinoma in situ of the cervix, or any other neoplastic disease with a&#xD;
             disease-free interval ≥ 5 years&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No gastric ulcers&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  No contraindications to corticosteroids&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No socioeconomic or geographic condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior cytostatic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent prednisone except for treatment of acute hypersensitivity reactions or&#xD;
             chronic low-dose treatment initiated more than 6 months prior to study entry (i.e., no&#xD;
             greater than 20 mg methylprednisolone or equivalent)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to chest&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since participation in another clinical study&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miklos Pless, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Winterthur KSW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans-Beat Ris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Naehrig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsspital-Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudoise</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik Loewenstein gGmbH</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za plucne bolesti</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Pluridisciplinaire d' Oncologie</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMH Onkologie/Haematologie</name>
      <address>
        <city>Rheinfelden</city>
        <zip>4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Serbia</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Tieu BH, Sanborn RE, Thomas CR Jr. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Review.</citation>
    <PMID>19086609</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

